AstraZeneca Buys ZS Pharma for $2.7 Billion

London: Britain's AstraZeneca said on Friday it had agreed to buy US biotech company ZS Pharma for $2.7 billion, pipping Swiss firm Actelion to the prize in the latest bout of deal-making for the hyperactive healthcare sector. AstraZeneca, which on Thursday lifted its full-year earnings forecast despite the eroding sales of some of its top-selling medicines, said it would pay $90 a share to secure ZS Pharma's proprietary technology ...